2 Cancer Stocks That Could Make You Filthy Rich
Developmental cancer companies can produce jaw-dropping returns on capital in short order. The core reason is that most of these companies are trading at a mere fraction of the commercial potential of their lead product candidates.
That's not surprising, given that most anti-cancer compounds fail at some point during the arduous and lengthy clinical trials process. On the rare occasion, however, these risky equities do sprout wings and learn to fly because of a surprise win in the clinic, a buyout agreement, or a licensing deal with a bigger pharma -- thus producing outsize gains for early shareholders.
Source Fool.com